A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Abroad (travel likely)Recruiting
Conditions
Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Bristol-Myers Squibb YH, Seoul, South Korea
Local Institution - 0001, Seoul, South Korea
Novotech Laboratory Korea Co., Ltd., Seoul, South Korea
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb